Lipoprotein(a) and coronary heart disease risk Santica M. MarcovinaRobert A. HegeleMarlys L. Koschinsky OriginalPaper Pages: 105 - 111
The role of C-reactive protein in cardiovascular disease risk Michelle A. AlbertPaul M. Ridker OriginalPaper Pages: 99 - 104
Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis Paul M. Ridker Clinical Trials Review Pages: 88 - 90
Current issues of novel risk factors for coronary disease and interventions for arrhythmias Valentin Fuster Invited Commentary Pages: v - vii
Doppler echocardiographic-guided diagnosis and therapy of heart failure John G. LainchburyMargaret M. Redfield OriginalPaper Pages: 55 - 66
Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: Patient selection, non-selective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy Robert MoskowitzMarrick Kukin OriginalPaper Pages: 47 - 54
Physical training as an adjunct therapy in patients with congestive heart failure: Patient selection, training protocols, results, and future directions R. HambrechtS. GielenG. Schuler OriginalPaper Pages: 38 - 46
Current experience with left ventricular assist devices in patients with congestive heart failure Donna ManciniMehmet OzAinat Beniaminovitz OriginalPaper Pages: 33 - 37
Review of a controlled trial of exercise rehabilitation after heart transplantation Thierry H. LeJemtel Clinical Trials Review Pages: 32 - 32
Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure Thierry H. LeJemtel Clinical Trials Review Pages: 31 - 31
Review of the cardiac insufficiency bisoprolol study II (CIBIS-II) Thierry H. LeJemtel Clinical Trials Review Pages: 29 - 30
Management of heart failure epidemiology and pathophysiology of heart failure Marc Klapholz Literature Alert Pages: 5 - 8
Management of heart failure epidemiology and pathophysiology of heart failure Stuart Katz Web Alert Pages: 1 - 4
